MedTrace Logo

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

NCT04592653 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-06-07

No results posted yet for this study

Summary

The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

Nemvaleukin alfa

IV infusion over 30 minutes

BIOLOGICAL

Pembrolizumab

IV infusion over 30 minutes

Sponsors & Collaborators

  • Mural Oncology, Inc

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Mural Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2024-07-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04592653 on ClinicalTrials.gov